Search PubMed⌕ Search

Biomedical subjects

E K Reddy

Publications and source records attributed to E K Reddy.

At least 37 records · Page 2Linked to original sources
PubMed1984

Radiation therapy for early glottic carcinomas.

From 1973 to 1978, 30 cases of early glottic cancers (TINOMO) were treated in the Department of Radiation Therapy, University of Kansas Medical Center. All 30 patients have a minimal follow-up of three years with a mean of 50.2 months, and 26 (86.7%) are alive with no evidence of disease. Radiation therapy failed in three (10%), two of whom were salvaged by subsequent surgery. Thus the overall control rate was 29/30 (96.7%). We recommend primary radiation therapy for these early lesions, reserving operation for cases of unsuccessful radiotherapy.

Carcinoma, Squamous Cell↗
PubMed1984

External radiation therapy of localized prostatic cancer.

From July 1975 to December 1980, 156 patients with localized carcinoma of the prostate received external radiation therapy at the University of Kansas Medical Center. Sixteen patients were lost to follow-up. The follow-up period for the remaining 140 patients ranged from 2 years to 7 years. Median follow-up period was 4.2 years. The overall survival according to stage was as follows: stage A2, 100 percent; stage B, 83 percent; and stage C, 53 percent. Corresponding disease-free survival was 91 percent, 70 percent, and 40 percent, respectively. Both stage and grade have great influence on survival. In stage B, about 44 percent of grade 3 tumors developed distant metastases compared with only 19 percent with grades 1 and 2 tumors. In stage C, 71 percent of grade 3 tumors showed progression of disease. A majority of patients with positive nodes showed progression of disease when compared with patients with negative nodes (75 percent vs 15 percent).

Aged↗
PubMed1984

Incidence of lymph node involvement in localized carcinoma of the prostate.

Bilateral pelvic lymphadenectomy was performed in 100 patients as a staging procedure. Sixty-one patients received iodine 125 radioisotope implant and 39 patients received external radiation therapy. The overall incidence of lymph node metastases was 27 percent. The incidence of lymph node involvement was 14 percent with clinical stage A2 disease, 3 percent with stage B1, 44 percent with stage B2, and 40 percent with stage C disease. The grade of the tumor influenced the incidence of lymph node metastases. Only 6 percent of grade I tumors had lymph node metastases, whereas 26 percent of grade II tumors and 71 percent of grade III tumors showed lymph node metastases.

Adenocarcinoma↗
PubMed1983

Chemodectoma of glomus jugulare.

A retrospective review of 17 patients with a diagnosis of chemodectomas of glomus jugulare is presented. The patients' age ranged from 32 to 63 years, with a female to make ratio of 4:1, with 14 females and 3 males. In the majority of the patients (15/17), the primary treatment was surgery, with 10/15 (70%) incidents of recurrence. Radiation therapy was used in 11 patients, in 7 for recurrence, in 2 as postoperative and in 2 as a primary therapy. The radiation dose ranged from 2200 to 5600 rad. The follow-up period ranged from 2 to 22 years. Sixteen patients were living with disease controlled at the last follow-up.

Adult↗
PubMed1981

Carcinoma of the uterine cervix: review of experience at University of Kansas Medical Center.

A total of 211 patients with a diagnosis of carcinoma of uterine cervix, managed by radiotherapy at the University of Kansas Medical Center between 1969-1975 was reviewed. There were 90 patients in Stage I, 65 in Stage II, 43 in Stage III, and 13 with Stage IV disease. Squamous cell carcinoma was found to be the most common histologic type. Twenty-three patients had shown uterine extension of the disease; of these, eight had adenocarcinoma. The majority of the patients received external whole-pelvic telecobalt therapy followed by a variety of intracavitary radium applications. The combined dose to point A ranged from 5000-13,000 rad. There were 166 patients followed for five or more years. Overall five-year survival was 74% (124/166). Survival by stage: IA--92% (12/13); IB--88% (55/62); IIA2--74% (23/31); IIB--58% (14/24); IIIA&B--64% (18/28); and IV--25% (2/8). The overall three-year survival was 73% (155/211). Thirty-three patients (33/211 = 16%) developed local recurrence, and five of these patients were salvaged by surgery. Surgery for complications was required in nine patients. Rectovaginal and vesicovaginal fistulae occurred in three patients (1.5%). Local recurrence and complications vs. dose and system used were analyzed.

Adenocarcinoma↗
PubMed1981

Chordoma.

Explore the source record for details and available documents.

Adult↗
PubMed1980

Results of radiation therapy in the treatment of epithelial carcinoma of the ovary.

Between 1967 and 1976, 82 patients who had epithelial carcinoma of the ovary and were treated with surgery and postoperative radiation therapy, respectively, were studied. Of these patients, 35% had Stage I disease, 16% Stage II, 45% Stage III, and 4% Stage IV. Serous cystadenocarcinoma was the histologic cell type in 54% of the patients, and mucinous cystadenocarcinoma was involved in 24%. Of the tumors, 35% were Grade 1, 34% Grade 2, 18% Grade 3, and 13% were unspecified. Survival at five years was 96% for Stage I patients, 60% for Stage II, and 60% for Stage III. No stage IV patient survived past two years. Stage III patients with no palpable tumor prior to radiation therapy did well, with 80% alive at more than two years, while only 10% of Stage III patients with palpable tumors prior to radiation therapy are alive. Patients with Stage III disease treated by whole-abdominal irradiation with a pelvic boost did better than those who received 3,000 rad or less to the pelvis. Radiation therapy continues to be an important treatment modality in epithelial carcinoma of the ovary, particularly in patients with minimal tumor burden.

Adenocarcinoma, Mucinous↗
PubMed1980

The search for new hypoxic cell radiosensitizers.

A number of newly synthesized compounds whose chemical structure suggested possible or remotely possible ability to radiosensitize hypoxic mammalian cells were studied in an in-vitro system. Those compounds that were not excluded because of insolubility or extreme cytotoxicity were tested for radiosensitizing ability. The correlation between chemical structure and radiosensitizing ability will be used for the rational design of additional compounds with a high probability of being effective hypoxic cell radiosensitizers. It is hoped that this will contribute to attempts to improve the cure rate of patients with malignant tumors through the use of radiation therapy and hypoxic cell radiosensitizers.

Cell Survival↗
PubMed1979

Malignant salivary gland tumors: role of radiation therapy.

Malignant salivary gland tumors are rare. They represent less than one percent of all head and neck tumors. Approximately three fourths of all salivary gland tumors occur in the major salivary glands.Traditionally, the treatment of choice for these tumors is surgery. The majority of these tumors reoccur after curative surgical procedures. Local recurrence rate following surgery varies with the histology, grade, and extent of the disease.In spite of high local recurrence rate following curative surgical treatment of these tumors, radiotherapy has seldom been used as an adjuvant to surgery. The value of elective postoperative radiation therapy for subclinical microscopic disease was not recognized. Review of the literature supports the improved local control rate with the use of immediate postoperative radiotherapy. Radiation therapy proved to be effective as an adjuvant to surgery. A local control rate of better than 40 percent can be achieved by radiation therapy as a sole modality in inoperable and locally advanced cases. Radiation therapy provides an excellent palliation for locally advanced tumors or symptomatic metastases.

Drainage↗
PubMed1978

A comparison of the effects of tumour growth delay of fractionated and single dose irradiation when administered with misonidazole (Ro-07-0582).

A majority of previous studies have shown the effectiveness of nitroimidazole derivatives, metronidazole and Ro-07-0582, in specifically sensitizing the hypoxic cell componenet of solid tumours to single doses of irradiation. The present study investigated the effects of nitroimadazoel Ro-07-0582 (0.75 mg/g) on the growth of MNU fibrosarcoma when administered with fractionated radiation therapy. Delay of tumour regrowth was recorded and was compared to single dose experiments using the sensitizer. The results show that fractionated radiotherapy with the sensitizer has an advantage over fractionated therapy alone (delay factor 1.58), but not over single dose therapy with the sensitizer (delay factor 2.6). This difference may be due to the sublethal repair from re-oxygenation in fractionated radiotherapy.

Animals↗